The US simvastatin Active Pharmaceutical Ingredient (API) marketplace experienced a decline in prices during December, which can be attributed to low demand, along with sufficient stocks, and a conservative buying attitude among pharmaceutical companies. Higher exports, especially in the Asia region, have been a factor in lowering prices, as companies made necessary adjustments to stay competitive in the global marketplace. The overall attitude of buyers was to wait and watch, leading to few simvastatin spot transactions during December. Despite this short-term weakness, market sentiment remains cautiously optimistic. Factors such as stabilizing logistics, reliability of shipments, and regularized prices for raw materials and energy are boosting supply chain confidence. Additionally, the purchasing of simvastatin by manufacturers would be expected to resume, considering the decrease in inventories and the momentum in the planning of production for the upcoming year. Looking ahead, the market for the simvastatin API would be expected to normalize in the first quarter of 2026, based on factors such as seasonally related restocking, renewed contract negotiation, and improved demand from finished dosage manufacturers.
